Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Somebody told about authorized shares of 2B,
But this is the structure of shares
Share Structure
Outstanding Shares 199,456,039 2/1/2019
Unrestricted 151,019,839 2/1/2019
can you help to clarify it ?
hold a long position averaged 0.013 here, not going to sell any until the news out
debts free with no more shares for dilution, a sign of partnership? a sign of BO? who knows but when it comes it booms!!!
https://finance.yahoo.com/news/brk-inc-returns-185-842-154500983.html
HENDERSON, Nevada, Feb. 19, 2019 /PRNewswire/ -- BRK, Inc. (OTC PINK: BRKK) is pleased to announce the final transaction numbers for the completed 3a10 with Continuation Capital are as follows:
Total debt and payables retired $169,631.28
Total shares reserved for transaction 300,000,000
Total shares issued for transaction 114,157,277
Total Shares returned to treasury 185,842,723
BRK announces the completion of the 3a10 with Continuation Capital, which has permitted management to pay off a mix of notes and professional service invoices. Daniel Serruya, President, CEO of BRK, Inc. commented, "this transaction allowed management to kick off its efforts toward restructuring the company. Next steps include removing larger creditors form the balance sheet while moving our technology forward and creating a number of new, profitable applications."
BRK's legal team is anticipating being able to file its declaration of damages against iSee Automation Inc. with the courts later this week. A further announcement will be made once the damages have been approved. BRK's Intellectual Property is the cornerstone of its shareholder's value and will be defended over all distribution channels.
About BRK, Inc.
BRK Inc. (OTC PINK: BRKK), established in 2008, is owner of the Helmet Camera intellectual property (patents-pending) that make the RefCam possible. With the acquisition of the live broadcast helmet camera patent, BRK is poised to enter sports marketing in a big way. iSee Sports Inc. is a wholly owned subsidiary of BRK, Inc.
The foregoing contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are intended to be covered by the safe harbor provisions of the federal securities laws. Forward-looking statements often contain words such as "will," "anticipate," "believe," "plan," "estimate," "expect," "intend," "is targeting," "may," "should," ''poised,'' and other similar words or expressions. Forward-looking statements are made based upon management's current expectations and beliefs and are not guarantees of future performance. Our actual business, financial condition or results of operations may differ materially from those suggested by forward-looking statements as a result of risks and uncertainties which include, among others, those described in any of our other filings with the SEC. In addition, such statements could be affected by risks and uncertainties related to: (i) commercialization of our newly-acquired helmet camera, (ii) continuing development and protection of our intellectual property, (iii) unexpected industry competition, (iv) the need to raise capital to meet business requirements, and (v) our ability to sell our products in order to generate revenues. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Any future public statements or disclosures modifying any of the forward-looking statements contained in or accompanying this news release, will be deemed to supersede such statements in this news release. Information on BRK Inc.'s website, http://www.brkincorporated.com does not constitute a part of this release.
Contact:
(702)-572-8050
shareholder@brkincorporated.com
Hi Kayak, you got to the point!
Considering the right to try policy, it is coming sooner
The very sincere and honest company it shows. The CEO Dr. Korenko has his professional and personal integrity, plus the help from a business smart, honest scam stock fighter Mr. Sharp, the company now is trustworthy and gains reputation and recognition, we will see.
Agree no more! A biopharma company even just in the stage of preclinical or early stage of clinical trials, no mention whether the pipeline will succeed or not, it is worthy of more than 10 M to couple 100 M. Vivos already has animal effectiveness approved products device as isopet, the very resistant soft tissue sarcomas were well controlled and proved by three lucky dog patients, how come human verison, the radiogel can not prevail? not mentioning so many types of solid cancers, such as breast cancer, prostate cancer, brain cancers and so on.
RDGL is very undervalued now, smart money is coming in especially from other countries, we will see!
great discussion, highly recommend new people here read through all the information in this hub and do the DD. isogel and radiogel have their very unique features that other companies do not have, therefore it will prevail in human trials as it has been showing effectively controlling the soft tissue sarcomas in dogs.
Great sharing of facts! RDGL will do well soon
thank you for your posts! Hope to connect by email.
thank you for your sharing, got in with position;
naturalshrimp.com/wp-content/uploads/Express-News-NaturalShrimp-Article.pdf
"from the News published on Feb.3rd,
The translucent, beady-eyed crustaceans zooming through the salty water are now into their 22nd week of growth. They’re about 5 inches long and
weigh about 18 grams apiece. They are gulping down food pellets dropped hourly with abandon, well on their way to a harvest weight of 23 grams"
by now two more weeks later, the shrimps are supposedly to grow to its harvest level. Hopefully, the harvest report will be released soon.
Get out of here then, lots of biotechs or companies have no revenue but they are priced much higher. RDGL has its product with innovation. It is being proved in animal solid cancer treatment, then being approved in human trials. Take chances when it is still much undervalued.
These are the sincere and solid facts but people with no faith overlook these. The Vivos has the approved products for solid cancers for animals, then for human trials. Radiogel is innovative injectable radiotherapy, for sure will take its place in the fight of against solid cancers. When news comes, people with little faith will kick themselves badly.
Great efficacy proof on canine soft tissue sarcomas treatment, 5 dog series will be finished soon, human clinical trials are the next.
Great News! Great sincere and honest progress report on dog sarcoma!
The greatest thing is:
4 dogs so far had isopet dosed, 2 dogs gave a great positive response with clear signs of healing, 2 dogs with news pending! 100% ORR( overall response rate) and stable disease (SD) can be expected;
got additional 350k shares! This treatment can go to human trials for sure. smart investors will pour in
Was this gone through the reverse-split recently? otherwise that was huge jump from 0.02 to 0.45. thank you for your input
Hi all-in888, just found this stock. on Jan 20th, the stock was 0.02 but how it is shotting up now at 0.45? thank you for any explanation.
good finding,somehow meaningful dots linked, have a good weekend
Nice DD, great insightful idea, hope the dots linked eventually, have a great weekend
Good information but why the name was not mentioned, no pay no gain.
can not agree more! A CEO who is paying bills for the company by his own credit card and getting compensation as shares definitely care about the company and investors.
please talk read DD here
yes I am the one of them
A must read from Mr. Sharp
http://www.clippercorporatepartners.com/2019/02/vivos-slays-dragon-initially-posted.html
what is making Vivos different now? here it is:
The Katzaroffs had taken as much as a million dollars out of Vivos over the final few years of Jim's tenure as CEO. In contrast, current CEO, Dr. Mike Korenko, has deferred his salary until the company is viable, and in fact, has paid a lot of the company's bills with his own credit cards.
i got one forth of it
No matter what is happening, I sold out other shares and buy as low as I can, I trust the management become the CEO paid the bill by his own credit card and got shares as compensation. He is greater that the greedy and ugly former one.
Hope your prediction is right and as expected
You will BE regret about that. Please do not call it scam, good things come with difficulties, if it is that easy, everyone can do it. Please do your DD before you say anything about this company. check the management of it.
It is the tough situation now, as being long, we are feeling we have been robbed badly, new greedy investors want more but hopefully, we are not suffered eventually.
As for the facts concerned, since CEO Korenko got compensation in shares, and with a clear and sincere explanation from Sharp about the difficult situation of the Vivos company has been going through, we still have faith and hope in this company, hope management do good things as they are in the same boat with loyal investors.
Definitely radiogel is not a cure for cancer, It is an advanced innovation which basically is radiotherapy but much less damage to normal tissue nearby the solid cancer, with combination of other therapy, like immunotherapy, it is more and more powerful.
George, you are great man with honesty and sincerity, with your great help, Vivos surely is on the right track of putting a great treatment into available choice for cancer patients.
this is good faith
some investors want the portion of Vivos, they are knowing what they are doing
bought in with a good discount and wait for long
Great message! Thank you
good points, during the journey of fighting cancers, there are many promising ideas or treatments in pre-clinical or clinical tests, but they always come with some limitations, such as a small population of patients has the positive response, or drug resistance, or severe side effects, therefore radiotherapy is still playing the irreplaceable role in cancer treatment. Isopet and Radiogel are the great inventions in advancing the radiotherapies. Yes there are always something new coming out but become of the unique features with Radiogel, this product will be eventually used in many solid tumors, like skin cancers, liver cancer, breast cancer and prostate cancer. Vivos is now too much undervalued when news comes, it would make longs laugh and shorts cry.
not really, good finding but it is too early phase, needing lots of proof and validation prior to human trial.
well said, Kayak, that is why we are here to support
Many cytotoxic anticancer treatments aim at fast-growing cells. But cancer stem cells are not fast growing, and they can escape these treatments. Then, when the treatment is over, they can generate cancer again.
Radiogel aims at solid cancers, with the advantages of getting into every part of solid cancer so destroy stem cancer cells inside there. With the combination of immunotherapies, Radiogel can play one of the major roles in the battle of fighting cancers. At the same time, because it spears the normal tissue around solid cancers, it is not affecting the life quality of cancer patients.